Fragment-Based Lead Discovery

Empowering Drug Discovery with Advanced Fragment Screening

⦾ Tailored Screening Libraries

⦾ 50 years of experience in drug discovery

⦾ Performed numerous screens for Biotech and pharma

⦾ Automated Data Analysis

Fragment-Based Drug Discovery

NMX Research and Solutions offers comprehensive services tailored to accelerating drug discovery, particularly focusing on fragment-based drug discovery (FBDD) by NMR and other orthogonal methods. NMX utilizes its Fragment-Based Drug Discovery Platform that intergrates NMX's proprietary curated librairies with NMR ans other biophysical technologies.

NMX offers:

NMR-Based Target Enablement

NMX assesses intrinsic parameters like protein folding, stability, multimeric state, and promiscuity using NMR experiments and other biophysical approaches to ensure the target's suitability for NMR screening and binding assays.

Fragment Screening Using Curated Libraries

NMX uses proprietary and tailored screening libraries experimentally curated to exclude aggregating agents and to ensure compounds possess optimal aqueous solubility, purity and structural consistency. Additionnally, fragments are intelligently pooled to enhance troughput, thereby facilitating rapid identification and characterization of hits from the fragment libraries. This dual focus on quality and and efficiency supports our streamlined approach to discovering high quality chemical matter.

Ligand Binding Studies

NMX uses NMR experiments to characterize binding interaction between ligand and disease target. To enhance the validation of these measurements, NMX also employs orthogonal biophysical methods, such as Microscale Thermophoresis (MST), Isothermal Titration Calorimetry (ITC), and Differential Scanning Fluorometry (DSF/nDSF).

Binding Affinity Determination

Binding affinity (KD) are measured by NMR experiments, and other orthogonal biophysical techniques, aiding in the quantitative assessment of ligand target interactions.

Structure-Based Drug Design

NMX employs NMR data alongside Computational drug discovery and X-ray crystallography approaches to optimize compounds for specific targets. They also perform binding site determination through various NMR techniques, like chemical shift mapping and competition assays, to refine drug design based on the structure-activity relationship (SAR).

Characterization of Compound Solution Behavior

They monitor compound solution behavior to avoid common drug discovery artifacts like aggregation and limited solubility. NMX has developed proprietary software and methods to streamline this process, which aids in prioritizing ligands for further evaluation.